Evidence map›Paper›PMID 40865509›Full record

ArticleInternational journal of surgery case reports2025

A case report of male breast cancer treated with breast-conserving surgery.

Kimiyasu Yoneyama, Motohito Nakagawa, Asuka Hara

Abstract readCase Reports
In one paragraph

Article in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kimiyasu YoneyamaDepartment of Breast Surgery, Hiratsuka City Hospital, Hiratsuka, Japan. Electronic address: key13213@yahoo.co.jp.
Motohito NakagawaDepartment of Breast Surgery, Hiratsuka City Hospital, Hiratsuka, Japan.
Asuka HaraDepartment of Breast Surgery, Hiratsuka City Hospital, Hiratsuka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and importanceMale breast cancer is a rare disease that accounts for less than 1 % of all breast cancer cases. The most common surgical treatment for male breast cancer is mastectomy, but breast-conserving surgery has been performed increasingly in recent years. This report describes a case of male breast cancer that was treated by breast-conserving surgery. CASE PRESENTATION: A 61-year-old man visited our hospital complaining of a painless mass in his left breast. Imaging revealed a well-defined cystic mass, aspiration of which revealed bloody fluid. Cytology was inconclusive, but the findings were suggestive of malignancy. A left lumpectomy was performed for diagnostic purposes. Postoperative pathology revealed invasive ductal carcinoma with a predominant intraductal component. The surgical margins were negative. The patient declined adjuvant hormone therapy and radiotherapy and has been kept under follow-up in the year since surgery. There has been no recurrence during this time. CLINICAL DISCUSSION: As in women, the goals of treatment for breast cancer in men are oncological safety and satisfactory cosmetic results. In the absence of specific guidelines for the treatment of male breast cancer, mastectomy is currently the standard treatment. However, in recent years, breast-conserving surgery has been performed for tumors that are discovered early and do not invade the nipple and areola. If curability and safety can be guaranteed, breast-conserving surgery can be considered for male breast cancer.

conclusionBreast-conserving surgery can be an effective treatment option in men with breast cancer.

Indexed as

Breast-conserving surgeryCase reportCosmeticMale breast cancerMastectomy

Identifiers

PMID40865509
PMCPMC12496512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.